US1270551013 - Common Stock

We assign a fundamental rating of **6** out of 10 to **CBT**. **CBT** was compared to 84 industry peers in the **Chemicals** industry. **CBT** has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on **CBT**. These ratings could make **CBT** a good candidate for value investing.

In the past 5 years **CBT** always reported a positive cash flow from operatings.

With an excellent **Return On Equity** value of **32.58%**, **CBT** belongs to the best of the industry, outperforming **96.43%** of the companies in the same industry.

With an excellent **Return On Invested Capital** value of **12.62%**, **CBT** belongs to the best of the industry, outperforming **89.29%** of the companies in the same industry.

Measured over the past 3 years, the **Average Return On Invested Capital** for **CBT** is significantly above the industry average of **7.47%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 11.72% | ||

ROE | 32.58% | ||

ROIC | 12.62% |

ROA(3y)8.48%

ROA(5y)4.41%

ROE(3y)27.87%

ROE(5y)12.94%

ROIC(3y)13.77%

ROIC(5y)11.62%

In the last couple of years the **Operating Margin** of **CBT** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 14.19% | ||

PM (TTM) | 11.03% | ||

GM | 22.32% |

OM growth 3Y16.94%

OM growth 5Y2.8%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y3.31%

GM growth 5Y-1.6%

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), **CBT** is creating some value.

The number of shares outstanding for **CBT** has been reduced compared to 5 years ago.

Compared to 1 year ago, **CBT** has an improved debt to assets ratio.

With a decent **Debt to FCF ratio** value of **3.41**, **CBT** is doing good in the industry, outperforming **79.76%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.98 | ||

Debt/FCF | 3.41 | ||

Altman-Z | 3.73 |

ROIC/WACC1.53

WACC8.24%

Looking at the **Current ratio**, with a value of **2.04**, **CBT** is in line with its industry, outperforming **48.81%** of the companies in the same industry.

A Quick Ratio of **1.30** indicates that **CBT** should not have too much problems paying its short term obligations.

The **Quick ratio** of **CBT** (**1.30**) is comparable to the rest of the industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.04 | ||

Quick Ratio | 1.3 |

The **Earnings Per Share** has been growing slightly by **5.95%** on average over the past years.

The **Revenue** has decreased by **-9.12%** in the past year.

EPS 1Y (TTM)0.17%

EPS 3Y37.49%

EPS 5Y5.95%

EPS growth Q2Q59.18%

Revenue 1Y (TTM)-9.12%

Revenue growth 3Y14.57%

Revenue growth 5Y3.93%

Revenue growth Q2Q-0.73%

The **Earnings Per Share** is expected to grow by **15.70%** on average over the next years. This is quite good.

EPS Next Y24.65%

EPS Next 2Y19.38%

EPS Next 3Y15.7%

EPS Next 5YN/A

Revenue Next Year1.52%

Revenue Next 2Y3.84%

Revenue Next 3Y3.79%

Revenue Next 5YN/A

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

With a **Price/Earnings** ratio of **15.44**, **CBT** is valued correctly.

66.67% of the companies in the same industry are more expensive than **CBT**, based on the **Price/Earnings** ratio.

When comparing the **Price/Earnings** ratio of **CBT** to the average of the S&P500 Index (**24.76**), we can say **CBT** is valued slightly cheaper.

Based on the **Price/Forward Earnings** ratio of **12.00**, the valuation of **CBT** can be described as reasonable.

Based on the **Price/Forward Earnings** ratio, **CBT** is valued cheaper than 84.52% of the companies in the same industry.

Compared to an average S&P500 **Price/Forward Earnings** ratio of **21.26**, **CBT** is valued a bit cheaper.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 15.44 | ||

Fwd PE | 12 |

Based on the **Enterprise Value to EBITDA** ratio, **CBT** is valued a bit cheaper than 75.00% of the companies in the same industry.

77.38% of the companies in the same industry are more expensive than **CBT**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 13.25 | ||

EV/EBITDA | 8.43 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as **CBT**'s earnings are expected to grow with **15.70%** in the coming years.

PEG (NY)0.63

PEG (5Y)2.6

EPS Next 2Y19.38%

EPS Next 3Y15.7%

Compared to an average industry **Dividend Yield** of **3.31**, **CBT** pays a bit more dividend than its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.76% |

The dividend of **CBT** has a limited annual growth rate of **3.84%**.

Dividend Growth(5Y)3.84%

Div Incr Years12

Div Non Decr Years19

DP20.55%

EPS Next 2Y19.38%

EPS Next 3Y15.7%

**CABOT CORP**

NYSE:CBT (4/19/2024, 7:04:00 PM)

After market: 92.01 0 (0%)**92.01**

**+1.32 (+1.46%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap5.10B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 1.76% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 15.44 | ||

Fwd PE | 12 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.63

PEG (5Y)2.6

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 11.72% | ||

ROE | 32.58% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 14.19% | ||

PM (TTM) | 11.03% | ||

GM | 22.32% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.06

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.98 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.04 | ||

Quick Ratio | 1.3 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)0.17%

EPS 3Y37.49%

EPS 5Y

EPS growth Q2Q

EPS Next Y24.65%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-9.12%

Revenue growth 3Y14.57%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y